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Abstract
Background Rare diseases pose transitioning challenges
owing to limited provider expertise and changing
healthcare systems. The timeframe and developmental
changes of emerging adulthood overlap with the transition
of patients with cystinosis from pediatric to adult-oriented
healthcare.
Methods This study utilized techniques of qualitative ground-
ed theory to explore the experiences of adults aged 18–47with
cystinosis, and their parents, with a focus on the transition to
adulthood and adult-oriented care. Forty-six individuals from
21 families were recruited online and at cystinosis conferences
to participate in focus groups and/or individual interviews.
The constant comparative method was used to conduct both
line-by-line and focused coding of verbatim transcripts.
Results The following elements were reported to be critical to
the transition to adulthood and adult-oriented care: gaining
skills and responsibility for disease management, progressing
toward autonomy while remaining connected to caregivers,
and having strong communication with and between
providers.
Conclusions Data analysis identified behaviors and relation-
ships that support and/or threaten autonomy and treatment
adherence. Participants described institutional, relational, and
practical barriers to transition. Suggestions for improving
transitioning include: identifying patient/family strengths and
improving pediatric–adult provider partnerships and commu-
nication. Further research is needed into the experience of
patients before and after transition to adult-oriented care.
Keywords Cystinosis . Transitioning . Adherence .
Emerging adulthood . Grounded theory
Introduction
Nephropathic cystinosis is a rare autosomal-recessive meta-
bolic disorder with an estimated prevalence of 1 case per
100,000 to 200,000 live births [1]. There are believed to be
500 nephropathic cystinosis patients in the USA and 2,000
worldwide, with about 15 new diagnoses per year [1]. Indi-
viduals diagnosed in infancy and early childhood face Fanconi
syndrome, growth delays, kidney failure, impaired vision, and
numerous other systemic health challenges [2, 3]. Treatment
involves a demanding medication regimen and eventual kid-
ney transplant. Before the availability of cystine-depleting
treatment, children with cystinosis reached end-stage renal
disease at age 9 or 10 [1, 3], requiring kidney transplant, and
faced early mortality by adolescence.
The availability of treatment in developed nations has
transformed cystinosis from a fatal to a chronic disease [4,
5], with the median age of survival currently at 27–30 years
[6]. Patients in the USA and other developed countries are
now surviving into their 5th decade of life and beyond [3, 7].
The need for kidney transplant is now commonly pushed back
to late adolescence and emerging adulthood [1, 6, 8]. Greater
availability of the oral medication Cystagon™, following
Food and Drug Agency (FDA) approval in 1994, allowed
for the slowing of disease progression [9] and for survival
into adulthood with lower rates of complications and death in
the USA and Europe [2, 10, 11]. Adherence to the treatment
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regimen has been correlated with improved outcomes [7], but
the side-effects of Cystagon™, particularly gastro-intestinal
distress [12, 13] (including nausea, vomiting, diarrhea), and a
distasteful odor on the skin and breath, have created chal-
lenges to adequate adherence in early adulthood [4, 6]. In
2013, the FDA approved an extended release drug,
Procysbi™, which promises to reduce side-effects and sim-
plify patients’ medical regimens [13–15] via 12-h dosing.
Also approved by the FDA in 2013, Cystaran™ eye drops
[16] replaced the cysteamine eye drops previously only avail-
able on a compassionate basis; the regimen continues to
include eye drops used once every waking hour.
Transitioning to adult systems of care
The term transitioning in the medical context first came into
use in the late 1980s, inspired by Surgeon General C. Everett
Koop [17], who observed that neonates whose lives he had
saved through surgery were now surviving into childhood and
adolescence (not unlike the survival of children with
cystinosis in the wake of cysteamine). A 2002 consensus
statement standardized the definition of healthcare
transitioning from pediatric to adult care as a process to
“maximize lifelong functioning and potential through the
provision of high-quality, developmentally appropriate
healthcare services that continue uninterrupted as the individ-
ual moves from adolescence to adulthood” [18].
The age range 18–25 (or even up to age 30) has been
identified as a time of rapid but normative developmental
change, as individuals move beyond childhood, while post-
poning the fully fledged responsibilities of adulthood [19].
Arnett characterizes “emerging adulthood” by five main fea-
tures: identity exploration; a sense of instability; a focus on
self; a feeling of being “in-between”; and a sense of possibility
[19]. For individuals living with cystinosis, the transition of
care from pediatric to adult-oriented care overlaps with the
timeframe of emerging adulthood, expectations for a greater
level of autonomy in disease and treatment management, and
changing educational, work, and insurance configurations.
The cystinosis community has identified the transition to
adulthood and adult-oriented care as a priority. Services in
resource-saturated pediatric systems of care often end abruptly
as patients move to adult-oriented providers. Patients and
providers may need time to connect personally, and across
systems or cultures of care [20]. Adult-oriented health pro-
viders may be less prepared to take on the care of former
pediatric patients, particular those with rare diseases [21, 22]
and may respond with trepidation or reluctance [23, 24],
particularly when conditions are evolving or new to their
practices. Community efforts to highlight the needs of newly
adult patients include the creation of a transition guide for
patients and families [25], attention to patient- and family-
oriented needs at professional and consumer conferences, and
advocacy-group presence at meetings of adult-oriented
nephrologists.
The ability to treat the condition does not equal cure, and
the long-term sequelae of survival with cystinosis, its treat-
ments, and the challenges of adherence remain to be under-
stood. This qualitative grounded theory study included focus
groups and interviews (Table 1) with adult cystinosis patients
and their parents, exploring experiences of living with
cystinosis in the context of changing medicine and the move-
ment from pediatric to adult-oriented systems of care.
Materials and methods
Sampling and recruitment
New York University‘s Committee on Activities Involving
Human Subjects (UCAIHS) approved the study protocol,
which originated in the School of Social Work. Inclusion
criteria required participants to be: either 18 years of age or
older with a diagnosis of cystinosis, or a parent of an individ-
ual 18 years or older with a diagnosis of cystinosis. Partici-
pants were recruited online through cystinosis advocacy or-
ganizations and in person at three cystinosis conferences.
Recruitment for, or participation in, research studies during
such conferences is not uncommon, and the community has
demonstrated a high response rate to recruitment in other
studies [26, 27]. Interested parties completed a brief online
or paper questionnaire to provide contact information confi-
dentially and to screen for inclusion/exclusion criteria. All
participants received information about the study and gave
informed consent before participation. Additional recruitment
continued via purposive and nominations sampling.
Data collection
Interview guides for both focus groups and interviews were
developed specifically for this study (Table 2). Each partici-
pating adult with cystinosis completed a demographic ques-
tionnaire (age, gender, education, employment and income)
and health history (age at diagnosis, transplant status, and age
at transplant; Fig. 1). Six focus groups were conducted be-
tween July 2011 and April 2012 at the Cystinosis Research
Network’s bi-annual Family Conference, the Midwest
Cystinosis Families gathering, and the Cystinosis Research
Foundation’s annual Day of Hopemeeting. These conferences
bring together cystinosis patients of all ages, family members,
healthcare providers, and researchers from across the USA
and around the world. Content typically includes forums
focused on disease education, current treatments and those
under investigation, disease research updates, psychosocial
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issues for patients and families, and opportunities for
socialization.
Seventeen individual semi-structured interviews were
completed between July 2011 and June 2012 (Table 1), with
adults with cystinosis and separately with parents who
responded to recruitment efforts, some of whom also partici-
pated in one or more focus groups. Interviews generally took
place in participants’ homes and lasted 90–120 min.
Focus groups and interviews were audio-recorded and
professionally transcribed. In the tradition of grounded theory,
field notes were written immediately after each focus group or
interview. Also, a case history was written for each patient/
family. Data collection continued until theoretical saturation
(the point at which qualitative data collection and analysis
yield additional language and incidents from participants, but
generates no new codes or categories) [28] was reached.
Data analysis
Substantive coding of transcripts was carried out in the
grounded theory tradition of constant comparative analysis,
in which data collection and analysis are simultaneous and
iterative [28–30]. This methodology was selected because of
its frequent use in exploratory, qualitative health research, and
its focus on conceptualization over description. Atlas.ti 7
(qualitative data analysis software) was used to organize tran-
scripts, codes, and memos [31].
Data analysis began with line-by-line coding of the first
three focus group transcripts to identify a preliminary list of
codes. These included open and in vivo codes (participant’s
own words), as well as focused codes addressing features of
emerging adulthood [19] and healthcare transitioning. For the
most part, the analysis utilized gerunds (−ing words) in coding
[32]—actions taken by participants to address their main
concern(s)—rather than descriptions of psychosocial status.
Focused coding was also utilized to identify specific psycho-
social and medical details, such as education, work, relation-
ship status, childbearing status, medical progression, medical
regimen; this coding schema was useful in mapping partici-
pants’ illness and developmental trajectories. A codebook was
created listing code definitions and parameters, brief memos,
and examples of each code, followed by another round of
coding to collapse and clarify emerging codes. To facilitate
translation of codes into findings, codes were grouped into:
individual, family, and community contexts; medical issues;
healthcare transitioning; and emerging adulthood.
When necessary in reporting findings, participants are de-
scribed by age, gender, or parental role, but demographic
information is used as little as possible (see the section
Strengths/limitations). Phrases in italics denote codes that
emerged through constant comparative analysis. Quotes are
Table 1 Study participants by age group (emerging adults 18–30 years of age with cystinosis; adults 30+years of age with cystinosis; parents of adults
with cystinosis), gender, and data collection type (focus group, individual interview, or both)






Participated in individual interview
and focus group
Total participants
Men aged 18–30 6 2 8
Men aged 30+ 4 4
Women aged 18–30 1 4 3 8
Women aged 30+ 2 2
Mothers 8 3 2 13
Fathers 8 2 1 11
Total participants 29 9 8 46 individuals (from
22 families)
Table 2 Interview guide for adult and parent participants
Interview guide Adults with cystinosis (age 18+) Parents of adults with cystinosis
Transmutation of
disease/illness
How has having cystinosis changed as you’ve gotten older? What
changes in the treatment of cystinosis have impacted you?
How has having cystinosis changed as your child has gotten




Do you think of yourself as an adult? How do you define adulthood? Do you think of your child with cystinosis as an adult? How
do you define adulthood?
Transitioning What are/were your concerns moving from pediatric to adult care? What are/were your concerns moving from pediatric to adult
care?
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included to further illustrate codes and share the experiences
of cystinosis patients and families with readers.
Results
The recognition of reprieve
“Wouldn’t it be cool to grow old?” declared one emerging
adult participant.
Participants were cognizant that, because of changing med-
icine, both cystinosis patients and their families experienced a
reprieve from the previously fatal nature of cystinosis. Indi-
viduals and families recognize the reprieve over time and
confront its variable impact on their health and psychosocial
status. Participants described how they had outlived the
prognostication of an early demise given to their parents at
the time of their diagnosis. Figure 1 illustrates the diagnosis
and transplant trajectories of participants, particularly showing
an increase in time to transplant. Participants recognized how
medical advances changed their expected lifespan and quality
of life. In stable if not perfect health, many expected to live
into adulthood, complete schooling, work, form romantic
partnerships, and become parents.
Parent participants spoke of celebrating birthdays that they
were told their child would not live to see: “The prognosis
they gave us was she probably won’t live to see her 16th
birthday. When it came time, I started planning a party…
you’re here, and we’re going to have a party.”
Transitioning
Outliving prognostication was accompanied by the need to
transition from pediatric to adult-oriented care. This shift
brought both opportunity for independence, and much fear
Fig. 1 Timelines for adult participants with cystinosis: time to diagnosis,
first and second transplant, transplant to present, and death, as of 2012.
Note: after taking part in two focus groups, participant P047 died in 2012,
after qualitative data collection had ceased. The parents of P34 contrib-
uted information, participating in a focus group and family interview, the
year following the participant’s death.
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and anxiety on behalf of cystinosis patients and families.
Participant mothers shared how frightened they were at the
prospect of losing trusted relationships with healthcare pro-
viders, and a level of attention and communication that had
helped keep their children alive:
It’s good now. It was horrific for a year, the transition
period, when he was leaving the pediatric doctor and
going to the adult…I cried—the pediatric people we’d
gotten so attached to. I mean you call them on the phone
and you get a call back within 20 minutes, which hasn’t
happened at all in the adult world. The pediatric people
knew cystinosis better than anybody, and had managed
to get him from near death to where he is today.
Participants shared how transitioning was not just a time
with a “sense” of instability [19], but a time of real risk. They
experienced health- and life-threatening lapses in treatment
because of not-uncommon challenges to medication adher-
ence, the change in care paradigms, and the lack of adult-
oriented providers who are knowledgeable about this rare
disease.
When I was in college I actually went four years without
going to a doctor at all, but I would always call the
doctor for my medicine.
His doctor, knowing he’s going off to college, just had a
come-to-Jesus talk with him and said, I’ve got a kid right
down the hall from me whose creatinine was 1 and now
it’s around 6. He said, I don’t want you to be one of
those statistics where this age group is verymuch at risk.
There was a big percentage of patients with cystinosis
who’d had transplants as children, and within two years
of moving into adults they lost the kidney
We started talking about [transition] when I was 16. It
was a bit difficult because we couldn’t go anywhere that
knew anything about cystinosis. We went [to another
hospital] for one consultation…They basically came out
with this bottle and said, oh, can you do a 24-hour urine
count? So I thought they obviously don’t know anything
about cystinosis if they don’t know how much we
[urinate].
Communication between providers was a particular source
of instability within the transition process. Participants and
families expressed concern about the gaps between pediatric
and adult providers.
There’s not as much communication as you would think
between the pediatric area and the adult nephrology
area. They pass their charts along, but there’s not
[communication]. Maybe that’s something that needs
to happen, more of a transition between the doctor’s
departments so that when these kids are moved on,
there’s communication.
So it was letting him, number one, be in charge of
everything, and then trusting that they’re going to be
able to understand this disease well enough to keep him
as healthy as he’s been.
There’s no central connecting point. I go to this doctor, I
go to this doctor, I go to this doctor, and they all fill out
the files that go into the same pile, but as far as direct
communication between them, I don’t think there’s
much.
If they could develop some sort of a serious transition
area between pediatric and adult with communications
between—so many kids did great in this [renal] popu-
lation and are dead within five years of this move.
Participants praised institutions that have created
transitioning clinics or otherwise facilitated the transitioning
process to provide continuity and stability:
When I went to the adult side of things, we just got stuck
into renal, whereas, cystinosis can affect all different
areas. So, you don’t get seen for the other bits. So [our
adult nephrologist] set up a cystinosis clinic, so every-
one can see him for the renal, but he’ll do it so on the
same day they can get [seen] for other things, ophthal-
mology, EKGs, speech and language therapy, things like
that.
Regimenting
Participants reported the importance of regimenting, creating
systems and structures to organize the management of
cystinosis. Over time, regimenting by parents sets the stage
for the transfer of power to greater self-management in ado-
lescence and adulthood. One participant, still in high school,
described, “catering to the medications,” adjusting her school
schedule and activities around side-effects, particularly fatigue
and stomach upset. Participants described the use of spread-
sheets, care binders, watches or phones set with reminder
alarms, pill boxes organized by day and time that track wheth-
er medications have been taken, or a “go-bag” ready for
outpatient visits and hospitalizations. Such tools supported
adherence and increasing autonomy, vital components of the
transition to adult-oriented care.
The pharmacokinetics of cysteamine and other supple-
ments, and the risk of rejection of a transplanted kidney, make
dose timing critical [33]. Parents described providing age-
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appropriate but straightforward information to their children
about why the medications were so vital, recognizing (or at
least hoping for) the reprieve that treatment offers and trying
to make consequences clear (whether disease progression or
increasing medication doses). Emerging adult participants
recalled when, during childhood, their parents enforced the
idea that medication-taking and medication time were not
flexible, but rather a usual part of one’s day, “like brushing
my teeth…an everyday thing that I had to do.” Participants
described how family strategies like these acclimated them to
their medication regimen, even though adherence remained at
times challenging, particularly during adolescence and the
move to college and/or independent living.
The medical regimen to manage cystinosis is more com-
plex than the tooth-brushing analogy implies, as a participat-
ing parent clarified, “54 pills and over 800 milliliters of liquid
medication every 24 hours”. Adult participants and their par-
ents described the challenge of fitting their complex regimen
into their day, particularly during college and work:
I don’t think there’s anybody that takes as much medi-
cine as he does that doesn’t forget once in a while.
The eye drops are the hardest to remember because
they’re every hour. You would think it wouldn’t be
because they’re every hour. It’s the total opposite, espe-
cially when you’re sitting in a three-hour class.
It gets in the way. Sometimes it’s as easy as you’re so
busy at work, you skip it once, and then it becomes twice.
It’s almost impossible for me to take the middle of the
night. I mean, I try to always get 3 but I never really try
to get the last one.
While regimenting provides skills and habits to support
adherence, participants reported that therapy-related factors
[34] (particularly the odor and side effects of cysteamine)
dictated many adherence-related decisions, particularly as par-
ticipants entered into social and romantic relationships as ado-
lescents and emerging adults. Participants also reported system-
ic and socio-economic factors [34], particularly insurance cov-
erage and drug costs, which support or deter adherence. Echo-
ing the view of adults with cystinosis that financial stability was
a part of their transition to adulthood, parents described fears
that, despite their efforts at regimenting, financial instability
might result in hidden non-adherence, “because they don’t have
any money and they don’t take their medicine.”
Transferring power
As children with cystinosis enter adolescence and then adult-
hood, families begin transferring power over disease and
treatment management from parent to child. This develop-
mentally appropriate task is made more challenging by the
need to manage the disease, while also experiencing other
transitions (in healthcare systems, living situations, education,
etc.). Both adult and parent participants discussed reluctance
or ambivalence about this transfer; parents were reluctant to
allow an adolescent or emerging adult to take greater respon-
sibility in their care, whereas some emerging adults were
ambivalent about accepting it. One participant felt that he
needed to “step forward” and take over his care as a way of
confronting his parents’ fears and making them “more com-
fortable” with his self-management.
Adult participants and parents expressed anxiety
around what could (or did) go wrong during attempts
at transferring power from parent to child. Parent par-
ticipants feared that their diminished participation in
their child’s care could decrease adherence and result
in disease progression or death. They struggled to relin-
quish control: “We’ve been so focused on keeping them
healthy and keeping up with their meds. It’s hard to
give that control over to them.”
Emerging adult participants approached the transfer of
power with trepidation as well. One admired how his mother
had managed all of the information and tasks involved in his
care, and feared his inability to do those things as well as she
had:“I never can remember as much as she does because she
worried so much, she always had it pounded in her brain and
had it organized.”
Parents and emerging adult participants defined self-care
similarly, as a debt repaid, a fair trade for the years parents
have worked to protect their child’s health:
We’ve done the right things. We’ve gave your medicine,
we’ve made sure you’ve taken it. We’ve got you to
school; we’ve got you to your appointments. It’s time
that you take over part of this. You need to do this.
Our parents having control of it all of our lives and then
us moving out, it’s hard on them. They feel very over-
protective because of the issues you have. It’s tough on
me too because they did so much for me.
Defining adulthood
The process of transitioning from pediatric to adult-oriented
care imposes a medico-legal definition of adulthood to which
participants had to respond (at age 16, 18, or 21, depending on
the medical center), whether they personally defined them-
selves as adults or not. One participant’s first hospitalization in
an adult medical unit forced a recognition, with some shock
and sadness, that “Oh my gosh, I’m an adult…I finally get a
room and they bring me up to the room and they tell me that
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my mom can’t stay. I remember just lying in the bed and
watching my mom walk down the hallway.”
The criteria participants used to define adulthood were
often pragmatic, including responsibility for specific tasks
and awareness of consequences of lapsed care. Participants
did not rely on traditional demographic markers, such as
finishing education, marriage or achieving parenthood [35].
When asked to define adulthood, participants with cystinosis
tied definitions of adulthood to self-care and financial self-
support: “You’re on your own, making your own decisions,
living with the consequences of those decisions, and being
able to financially take care of yourself.”
Participants described thinking of oneself as an adult as a
process, not a specific moment in time. They saw themselves
as “in between,” “not there yet,” or as an “incomplete adult.”
I have to understand my disease and have the doctors
and stuff squared away. I know I can do everything; it’s
just the getting there.
I feel like I’m in between. I don’t quite feel like a high
school kid, but I don’t quite fee like a complete adult.
I’m an incomplete adult.
I feel like an adult if I’mpayingmy own bills and all that
stuff, not needing their help for that. That’s what I find
difficult, being a complete adult.
Parent participants also tied perceptions of adulthood to
self-care and financial management. Some noted concerns
about maturity and recognized that their perceptions of their
adult children with cystinosis were changing (or needed to).
I still have trouble thinking of [him] as an adult because
he still lives at home with us. And there are things that
he still just doesn’t do.
I’m hopeful he’ll be able to get a job, be independent,
take care of himself. That would be icing on the cake of
his life, being able to do those things.
[She’s] so organized; she takes care of everything. But
she’s still my baby/
I feel like we’re just starting to think of him as an adult.
Connected autonomy
Adult participants with cystinosis described wanting a sense
of connected autonomy, being independent yet staying con-
nected to their family. They were willing to ask for and accept
help, both in daily living and in the event of a medical crisis. In
maintaining connected autonomy, emerging adults (and
adults) steered the management of their illness and their
healthcare, and involved family and significant others as
necessary. They reported the ability to call on family to help
instrumentally and emotionally when needed. Depending on
the participant’s health status and age, such help entailed
accompanying patients during medical visits, helping with
prescription refills, talking with college staff, managing
childcare or domestic tasks, or giving input into healthcare
decisions.
When I was in the hospital, after transplant, I needed
some blood. I was like, ‘oh, I don’t want it.’ But my
mom was there and said ‘you need it.’ She helped me
make the right decision. It was my decision. I had to sign
the consent. A lot of those medical choices I made
myself but with the help and opinion of my mom or
family.
One mother spoke practically about planning for the chal-
lenges of her daughter living independently (given her muscle
weakness), envisioning a future in which she would be in-
volved in her daughter’s daily life:
If she was going to be living on her own, things that I do
for her, how can we make it that she can do things for
herself? If she were going to be doing her own grocery
shopping, she can’t buy a gallon of milk. She would
have to buy a half a gallon. So that she can carry it and
tip it. Independence is going to take a lot of planning…a
lot of assistance.
For some participants, the need to rely on family was a
source of disappointment, and a threat to autonomy:
I had some health issues so I moved back home, which
was very difficult for me because I like to be very
independent, and the whole reason I think I moved
[away] was because it was basically the farthest that I
could go.
For others, connected autonomy provided the safety of
knowing that parents would be there when needed, even while
adults with cystinosis were striving to live independently.
They’ll always be there to help me, but I just want to let
them know I can hang out myself and if I ever need any
help I know they’ll be there.
You always want help. Help’s great. But at the same
time you want them to carry on with their lives too.
For partnered young adults, connected autonomy extended
from family of origin to family of choice. Adults with
cystinosis who entered into long-term relationships consid-
ered the implications of chronic illness and possible
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progression, the need for assistance, now or in the future, and
decisions about child-bearing or adoption. Yet, they reported
expectations and motivations of partners and parents that were
quite different. One participant described how her mother
“screened” her fiancé, recognizing a need for a partner willing
to be a caregiver. When that relationship was unsuccessful,
this participant envisioned her parents as protective eagles
watching over her:
I do feel that I need to be with my parents because of
cystinosis. I’m not just transplanted. I have cystinosis. I
do need that protection still. I don’t think my kidney
would have failed if I was with them. Because my
mom—she wasn’t begging me, but she would say, did
you take the medicine? So I feel like I do need that
protection, that eagle covering me.
Discussion
The movement from regimenting by parents, to the transfer of
power throughout adolescence and emerging adulthood, the
roles and responsibilities seen as part of defining adulthood,
and the maintenance of connecting autonomy represents a
positive pathway for the management of illness and improved
outcomes for those diagnosed with cystinosis in childhood.
Reflective of Arnett’s features of emerging adulthood [20],
participants described being in-between in their definitions of
adulthood and in descriptions of institutional and practical
barriers to transition from pediatric to adult-oriented care,
and shared concerns about instability, personally, financially,
and medically. They also spoke of their lives with a great deal
of positivity and possibility, as they pursued higher education,
traveled, formed long-term relationships, and started families.
The reprieve offered by changing medicine over the last
few decades does not guarantee a smooth or positive trajectory
throughout the lifespan. As Fig. 1 details, the age at transplant
for many participants is now in late, rather than early, adoles-
cence—sometimes occurring just as they are starting college
or living with peers. Aspects of the disease may force a step
back from developmentally appropriate autonomy to greater
dependence—be it a medical crisis, a need for dialysis, trans-
plant, or transplant rejection. Such episodes may reverse the
transfer of power, at least temporarily. Health concerns, com-
bined with other socio-economic drivers, may maintain or
return emerging adults to the nest. At times a disappointing
realization, it is difficult to let go of autonomy once one has
claimed it. Providers may consider tempering expectations of
self-management and autonomy as part of transitioning with a
realistic need for support throughout the lifespan, and a de-
velopmentally appropriate renegotiation of roles.
Transitioning
Adult patients with cystinosis and parents both identified how
these adults are attempting to assume greater responsibility for
self-care with fewer institutional supports and in a new and
unknown medical environment. Ongoing efforts within the
professional pediatric nephrology community seek to address
gaps in transitioning for the broad spectrum of pediatric renal
patients [36–39]. The cystinosis community has identified
healthcare transitioning and the transition to adulthood as
priorities for research and programming [25]. Results from
this study and from others [40] suggest that transitioning must
be viewed as a process, a flexible one at that, not simply a
transfer date (one to be approached with dread). Within pedi-
atric patient–family–provider relationships, building self-care
and self-advocacy skills before the transfer of care seems
paramount. These skills many benefit both adherence and
interactions with future providers. Simultaneously, education
and engagement of adult-oriented nephrology teams (and
other specialists and primary care providers) in assuming the
care of patients now surviving with cystinosis is vital. The
visible demonstration of communication and partnering be-
tween pediatric and adult-oriented providers can give assur-
ance to transitioning patients and families that they are gaining
new allies, not losing a trusted safety net. To support such
relationship-building, cystinosis advocacy groups have taken
opportunities to exhibit at professional conferences for adult-
oriented nephrologists, such as the American Society of
Nephrology’s Kidney Week.
Adherence and practice implications
As described by participants, the survival of individuals with
cystinosis relies in no small part on the effort, time, dedication,
and focus of families in both obtaining and maintaining ade-
quate treatment and fitting illness into family life. There is no
reprieve without treatment. The challenges of medication
adherence for adolescents with renal disease have been well-
documented [36, 41, 42]. The challenges of adherence with
cystine-depleting agents are recognized by researchers and
healthcare providers, and continue to have an impact on the
search for more tolerable and longer acting treatment options.
Despite the promise of research in the areas of stem cell
transplant and gene therapy [43, 44] and recent FDA and
EMA approval of two drugs for cystinosis [13, 16], patients
and families face a heavy task burden in managing the illness.
Recognizing patient and family strengths, building on the
regimenting styles and tools they have adopted, and commu-
nicating this understanding to accepting adult-oriented pro-
viders, may make transitioning a smoother, more positive
process.
Inability to afford medications has been a major concern
for adults with cystinosis, and their families, in the USA.
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Insurance coverage and healthcare utilization has been an area
of particular instability for emerging adults [45, 46]. For those
with cystinosis, changing coverage and access to care may
create real risk. Families responding to the 2011 Living with
Cystinosis survey [27], a precursor to this study, expressed
great concerns in this area. While most families (in the USA)
were relieved by the extension of dependent coverage to age
26 and the elimination of pre-existing condition criteria as a
result of the Affordable Care Act [47], some were fearful of
losing access to life- and transplant- preserving medications if
they, or their families, lacked insurance coverage or adequate
finances. It is imperative that transitioning discussions with
cystinosis patients and their families include plans and re-
sources for maintaining health coverage and financial stability
[40].
Strengths/limitations
Criteria for assessing qualitative and grounded theory research
include trustworthiness [48], credibility, usefulness [29],
transferability, and confirmability [30]. Interview guides for
this study were developed with key informants, including
adult and adolescent members of the cystinosis community,
parents, healthcare providers, and other researchers. Peer
debriefing [30, 49] was available from fellow social work
and health researcher’s participation in the Cystinosis Re-
search Network’s Adult Care Excellence initiative, in devel-
oping the Living with Cystinosis survey [27] and the Bridges
to the Future Transitioning Guide [25] also provided for
prolonged engagement [30, 49] and insight into the con-
cerns of the community. Themes similar to the concepts
identified in this study have also been described by patients
and families in advocacy organization newsletters and so-
cial media, providing triangulation [30, 49] with publicly
available information.
The specific disease population, sample size, qualitative
nature, and methods of this study provided rich data regarding
the experiences of adults with cystinosis, which may or may
not be comparable with the experience of individuals with
other chronic and rare diseases, or with other birth cohorts
affected by cystinosis. The sample is based primarily in the
USA; the experience of living with cystinosis, and of
transitioning to adulthood and adult-oriented care, outside of
the USA and/or other developed nations, with potentially
limited access to cystine-depleting therapy, and differences
in organ allocation for transplantation, may be quite different
[50, 51].
One risk of the “thick description” made possible through
this qualitative method is the risk of inferred identification
[52]; the small size and high level of connectedness within the
cystinosis community increases challenges to anonymity and
confidentiality. This presents a particular challenge in the
dissemination of findings with meaningful detail, while
protecting the identity of individual participants who are well
known to each other, to providers, and to other researchers.
Classic grounded theory methodology [53] helped to organize
data around codes and concepts rather than around descrip-
tions of individual participant or family experiences.
Conclusions
Findings from this study conceptualize behaviors and rela-
tionships that support and/or threaten autonomy, disease self-
management, and treatment adherence during this time of
transition to adulthood and adult-oriented care. Imbuing indi-
viduals diagnosed in childhood with cystinosis, or other forms
of rare or chronic illness, with the skills and philosophy for
self-care, negotiating the transfer of power, and creating a
sense of connected autonomy allow them, as adults, to engage
in age-appropriate developmental tasks. The progressive na-
ture of the illness, and the demands of medication regimens,
underlie much (but not all) decision-making around higher
education, vocations, romantic relationships, and family plan-
ning. Further research into the experience of emerging adult-
hood and adulthood with rare and chronic disease, during and
following transition to adult-oriented care, is needed to con-
tinue improvements in quality of care, health outcomes, and
quality of life.
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